NEW YORK, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar ...

Biohaven (NYSE:BHVN – Free Report) had its price objective lowered by Morgan Stanley from $69.00 to $63.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed” data ...

Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Biohaven in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now expects that ...